Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Interaction Between Decidual Cells and NK Cells in Endometriosis (PAINLESS)

11. Juni 2026 aktualisiert von: Hopital Foch

Interaction Between Decidual Cells and Natural Killer Cells in Endometriosis: A Prospective Pilot Case-Control Study

Endometriosis is a chronic gynecological disease characterized by the presence of endometrial-like tissue outside the uterus and is frequently associated with pelvic pain and infertility. Increasing evidence suggests that immune dysfunction may contribute to the development and persistence of the disease.

The purpose of this prospective case-control study is to compare immune cell characteristics in women with deep endometriosis and women without endometriosis during the secretory phase of the menstrual cycle. Participants will undergo collection of clinical data, blood samples, endometrial samples, and vaginal microbiota samples. For participants undergoing clinically indicated pelvic surgery, additional biological samples may be collected during the procedure. The study aims to improve understanding of the immune mechanisms involved in endometriosis and to identify potential biomarkers associated with the disease.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Endometriosis affects approximately 10-15% of women of reproductive age and represents a major public health concern. Despite its high prevalence, the pathophysiological mechanisms underlying the disease remain incompletely understood. Increasing evidence suggests that alterations in the immune environment of the endometrium may contribute to the establishment and progression of endometriosis. In particular, uterine immune cells may play a role in regulating local inflammation and tissue homeostasis. Characterizing these immune mechanisms may improve understanding of disease development and identify potential biomarkers associated with endometriosis.

PAINLESS is a prospective, single-center, pilot case-control study conducted at Foch Hospital (Suresnes, France). The study will enroll 50 adult women, including 25 participants with confirmed deep endometriosis and 25 control participants without endometriosis.

Biological samples will be collected during the secretory phase of the menstrual cycle (days 16-24). Depending on clinical management, study procedures may include:

  • Collection of demographic and clinical data
  • Assessment of symptoms and quality of life
  • Blood sampling
  • Endometrial sampling
  • Vaginal microbiota sampling
  • Collection of additional biological specimens during clinically indicated pelvic surgery.

Biological samples will be analyzed to characterize immune cell populations, evaluate soluble immune mediators, investigate associations with hormonal and clinical parameters, and explore biological mechanisms involved in endometriosis.The primary objective is to compare the expression of immune-related markers in endometrial and peritoneal samples obtained from women with endometriosis and controls. Secondary objectives include characterization of immune cell phenotypes and functions, evaluation of immune-related soluble factors, investigation of interactions between immune and endometrial cells, assessment of correlations with hormonal and clinical data, exploratory genetic analyses, and creation of a vaginal microbiota biobank. Results from this pilot study are expected to provide preliminary data for future research aimed at improving the understanding, diagnosis, and management of endometriosis.

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Endometriosis Group
  • Female participant aged 18 years or older.
  • Confirmed diagnosis of deep endometriosis by imaging or surgery.
  • Pelvic pain and/or severe dysmenorrhea (Visual Analog Scale > 4).
  • Premenopausal.
  • No contraceptive or hormonal treatment during the study menstrual cycle.
  • Affiliated with a health insurance system.
  • Able and willing to provide written informed consent.
  • Control Group
  • Female participant aged 18 years or older.
  • No diagnosis of endometriosis.
  • Premenopausal.
  • No contraceptive or hormonal treatment during the study menstrual cycle.
  • No chronic pelvic pain or severe dysmenorrhea (Visual Analog Scale < 4).
  • Affiliated with a health insurance system.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Current infection.
  • Active cancer.
  • Active autoimmune disease.
  • Concomitant hormonal treatment.
  • Pregnancy.
  • Participant under guardianship or legal protection.
  • Participant deprived of liberty.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Endometriosis Group
Adult women with confirmed deep endometriosis undergoing collection of clinical data and biological samples, including blood, endometrial tissue, vaginal microbiota samples, and, when clinically indicated, additional samples collected during pelvic surgery.
Verfahren: Biological Sample Collection
Collection of blood samples, endometrial samples, vaginal microbiota samples, and surgical specimens when clinically indicated for immunological and biomarker analyses.
Aktiver Komparator: Control Group
Adult women without endometriosis undergoing collection of clinical data and biological samples, including blood, endometrial tissue, vaginal microbiota samples, and, when clinically indicated, additional samples collected during pelvic surgery.
Verfahren: Biological Sample Collection
Collection of blood samples, endometrial samples, vaginal microbiota samples, and surgical specimens when clinically indicated for immunological and biomarker analyses.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
CD39 Expression on Natural Killer Cells in Endometrial and Peritoneal Samples
Zeitfenster: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Comparison of CD39 expression on natural killer (NK) cells in endometrial and peritoneal samples collected from women with deep endometriosis and women without endometriosis.
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
NK Cell Cytotoxic Function
Zeitfenster: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Assessment of NK cell cytotoxic activity through degranulation markers and cytokine production in biological samples.
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Endometrial and NK Cell Interactions
Zeitfenster: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Evaluation of interactions between endometrial cells and NK cells using tissue-based analyses.
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Ex Vivo Modulation of NK Cell Function
Zeitfenster: Following sample collection, up to study completion (16 months)
Evaluation of the effects of cytokine stimulation on NK cell function and endometrial cell responses in laboratory assays.
Following sample collection, up to study completion (16 months)
Association Between Hormonal Levels and NK Cell Profile
Zeitfenster: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Correlation of estrogen and progesterone levels with NK cell characteristics and immune markers.
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Association Between Clinical Characteristics and Immune Markers
Zeitfenster: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Correlation between clinical features of endometriosis and immunological findings.
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
Genetic Biomarker Associations
Zeitfenster: At sample collection and laboratory analysis up to study completion (16 months)
Assessment of associations between genetic markers and immunological findings.
At sample collection and laboratory analysis up to study completion (16 months)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Hopital Foch

Ermittler

  • Hauptermittler: Marie CARBONNEL, MD, Foch hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juni 2026

Primärer Abschluss (Geschätzt)

1. Oktober 2027

Studienabschluss (Geschätzt)

1. Oktober 2027

Studienanmeldedaten

Zuerst eingereicht

11. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. Juni 2026

Zuerst gepostet (Tatsächlich)

17. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2024_0074

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Endometriose

Klinische Studien zur Biological Sample Collection

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Kenya

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren